Page last updated: 2024-09-03

vadimezan and cediranib

vadimezan has been researched along with cediranib in 1 studies

Compound Research Comparison

Studies
(vadimezan)
Trials
(vadimezan)
Recent Studies (post-2010)
(vadimezan)
Studies
(cediranib)
Trials
(cediranib)
Recent Studies (post-2010) (cediranib)
27216101279102204

Protein Interaction Comparison

ProteinTaxonomyvadimezan (IC50)cediranib (IC50)
Platelet-derived growth factor receptor betaHomo sapiens (human)0.005
Fibroblast growth factor receptor 1Homo sapiens (human)0.026
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.036
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.005
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.003
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0016

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Döme, B; Magyar, M1

Reviews

1 review(s) available for vadimezan and cediranib

ArticleYear
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
    Magyar onkologia, 2008, Volume: 52, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones

2008